2 dabbagh measles rubella global update - who...date of slide: 20 august 2018 85% 67% 173,330 5 0...
Post on 25-May-2020
3 Views
Preview:
TRANSCRIPT
Measles and Rubella Targets
Global: World Health Assembly, 2010Milestones by 2015:1. MCV1 coverage ≥ 90% national & ≥ 80% in
every district2. Measles reported incidence <5 cases/million3. Measles mortality reduction of 95% vs. 2000
Regional elimination (GVAP, 2012):By 2015:– Elimination of measles in 4 WHO Regions – Elimination of rubella in 2 WHO Regions
By 2020:– Elimination of measles & rubella in 5 WHO Regions
3
Measles Global Annual Reported Cases and MCV1* and MCV2** Coverage, 1980-2017
*MCV1 coverage: first dose of measles-containing vaccine as estimated by WHO and UNICEF.**MCV2 coverage estimates are only available from 2000 when global data collection started, however some countries introduced MCV2 earlier. Source: WHO/IVB database & WHO/UNICEF coverage estimates 2017 revision, July 2018. 194 Member States. Date of slide: 20 August 2018
85%
67%
173,330
5
0 2,100 4,2001,050 Kilometers
Global Milestone #1: MCV1 coverage ≥ 90% national & ≥ 80% in every district
Immunization coverage with 1st dose of MCV in infants, 2017
<50% (8 countries or 4%)50-79% (27 countries or 14%)80-89% (41 countries or 21%)90-94% (40 countries or 21%)
Not available
Not applicable
>=95% (78 countries or 40%)
Source: WHO/UNICEF coverage estimates 2017 revision, July 2018. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization. 194 WHO Member States. Date of slide: 15 July 2018
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2018. All rights reserved
• 118 (61%) countries have >90% coverage with 1st dose of MCV
• 44 (23%) with MCV1 coverage ≥ 90% national and ≥ 80% in every district
6
98 106 110 112 117 122 125 128 130 134 136 138 144 148 154 160 164 167
0
20
40
60
80
100
0
50
100
150
20020
00
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
% c
over
age
num
ber o
f cou
ntrie
s
Number of countries introduced 2nd dose of measles MCV2 coverage
Number of countries having introduced 2nd dose of measles containing vaccine (MCV2) and global MCV2 coverage,
2000-2017
Source: WHO/UNICEF coverage estimates 2017 revision, July 2018, and WHO database, as at 06 July 2018.Immunization Vaccines and Biologicals, (IVB), World Health Organization.194 WHO Member States. Date of slide: 15 July 2018.
27 countries not yet introduced MCV2
7
Countries with rubella vaccine in the national immunization programme and planned introductions in 2018
Data source: WHO/IVB Database, as of 15 May 2018Map production Immunization Vaccines and Biologicals (IVB),World Health Organization
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2018. All rights reserved.
Introduced* to date (167 countries or 86%)Planned introductions in 2018 (2 countries or 1%)Not Available, Not Introduced/No Plans for 2018
(25 countries or 13%)Not applicable
* Includes partial introduction
Ø Global RCV coverage , 2017= 52%
Ø 25 countries lack RCV
0 2,400 4,8001,200Kil
8
Global Milestone #2: Measles Incidence <5 cases/million
2010: 60% countries <5 cases/million2017: 61% of countries <5 cases/million
9
Global Milestone #395% Reduction in Measles Deaths
20.4 million deaths prevented from 2000-2016 by measles vaccination
No. o
f mea
sles d
eath
s
Year
Measles deaths
down 84%!
10
Num
ber o
f con
firm
ed m
easl
es c
ases
Reg
iona
l rat
e pe
r 1,0
00,0
00
Measlesoutbreaksintheposteliminationera.TheAmericas,2003-2018*(incidenceratepermillion)
Regional verification of
measles elimination
N= 6,989 (6.9)
Source: SysVPD (ISIS) and country reports sent to PAHO/WHO. *Data as of epidemiological week 40-2018
13
Sources: Ministry of Health of Venezuela. *Data as of epidemiological week 32 –2018. Pan American Health Organization
Reported Measles cases by Epidemiological Weeks, Venezuela 2018
14
Measles case distribution (WPR), 2014-2018
2014
-01
2014
-02
2014
-03
2014
-04
2014
-05
2014
-06
2014
-07
2014
-08
2014
-09
2014
-10
2014
-11
2014
-12
2015
-01
2015
-02
2015
-03
2015
-04
2015
-05
2015
-06
2015
-07
2015
-08
2015
-09
2015
-10
2015
-11
2015
-12
2016
-01
2016
-02
2016
-03
2016
-04
2016
-05
2016
-06
2016
-07
2016
-08
2016
-09
2016
-10
2016
-11
2016
-12
2017
-01
2017
-02
2017
-03
2017
-04
2017
-05
2017
-06
2017
-07
2017
-08
2017
-09
2017
-10
2017
-11
2017
-12
2018
-01
2018
-02
2018
-03
2018
-04
2018
-05
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
22000
Month of onset
Num
ber
of m
easl
es c
ases
Viet NamSingaporeRepublic of KoreaPhilippinesPapua New GuineaOthers
MongoliaMalaysiaJapanChinaAustralia
Notes: Based on data received 2018-07 - Data Source: IVB Database
15
Measles case distribution (EUR), 2014-2018
2014
-01
2014
-02
2014
-03
2014
-04
2014
-05
2014
-06
2014
-07
2014
-08
2014
-09
2014
-10
2014
-11
2014
-12
2015
-01
2015
-02
2015
-03
2015
-04
2015
-05
2015
-06
2015
-07
2015
-08
2015
-09
2015
-10
2015
-11
2015
-12
2016
-01
2016
-02
2016
-03
2016
-04
2016
-05
2016
-06
2016
-07
2016
-08
2016
-09
2016
-10
2016
-11
2016
-12
2017
-01
2017
-02
2017
-03
2017
-04
2017
-05
2017
-06
2017
-07
2017
-08
2017
-09
2017
-10
2017
-11
2017
-12
2018
-01
2018
-02
2018
-03
2018
-04
2018
-05
2018
-06
0
1000
2000
3000
4000
5000
6000
7000
8000
Month of onset
Num
ber
of m
easl
es c
ases
UkraineSerbiaRussian FederationRomaniaOthersKyrgyzstan
ItalyGermanyGeorgiaFranceBosnia and Herzegovina
Notes: Based on data received 2018-07 - Data Source: IVB Database16
Scorecard on Verification of Elimination, Sept. 2018
WHO Region(no. countries)
Regional Verification
Commissions Established
Elimination Achieved
No. of countries % of countries
Americas (n=35) Yes Measles: 34Rubella: 35
97%100%
Europe (n=53) Yes Measles: 37Rubella: 37
70%70%
Western Pacific (n=27) Yes Measles: 6Rubella: 2
22%7%
Eastern Mediterranean (21) Yes - -
South-East Asia (n=11) Yes Measles: 4 36%
Africa (n=47) Yes - -
TOTAL Measles: 81 (42%)Rubella: 74 (38%)
EUR: 6 additional countries interrupted measles transmission for >12 m but <36 m.5 additional countries interrupted rubella transmission for >12 m but <36 m.
17
Key Regional Achievementsl One Region achieved and sustained rubella elimination (AMR). Rubella elimination verified in an
additional 39 member states.
l Three regions with all countries having introduced RCV (AMR/EUR/WPR).
l India and Indonesia introducing rubella vaccine in 2017-2018 (>470 million targeted through SIAs). Six countries in SEA verified as having controlled rubella
l 12 AFR countries near measles elimination* and an additional 14 on track for the 2020 goal.
l 7 EMR countries are close to measles elimination with 4 (Bahrain, Jordan, Oman & Palestine) reporting interruption of transmission for more than 36 months (pending verification)
l High coverage with 2 doses of MCVs (AMR/EUR/WPR).
l RVC established in all 6 Regions. With three regions verifying rubella elimination (AMR/EUR/WPR).
*Algeria, Burkina, Cape Verde, Rwanda, Eritrea, Gambia, Ghana, Mauritius, Senegal, Seychelles, Sao Tome, Zimbabwe
18
Key Regional Challenges (1)
l Gaps in population immunity due to:
– Weak and fragile health systems in many countries (AFR/EMR)
– Vaccine demand and hesitancy (EUR; SEAR)
– Civil unrest, famine, active conflict, socio-economic/political crisis (EMR/PAHO)
– Declining maternal antibody levels
l Susceptible distributed across increasingly wide age groups, making eventual elimination
more expensive & more technically difficult (EUR/EMR/SEAR/WPR).
l Outbreaks affecting adolescent and adults, healthcare workers, migrants, indigenous and
religious groups (EUR/PAHO/WPR/SEAR)
l Infants <1 year old affected by measles (EUR/EMR/SEAR/WPR/PAHO)
19
Key Regional Challenges (2)
l Maintaining elimination in the face of ongoing importations both within and between regions (PAHO/EUR)
l No target for rubella /CRS elimination (AFR/EMR/SEAR)
l No target date for rubella elimination (WPR)
l Low political commitment to elimination in some member states
l Inadequate resources to fully implement recommended strategies:– Inadequate resources for wide age-range campaigns to address population
immunity gaps– Steadily declining resources through M&R Initiative– MICs left out– Lack of resources for surveillance (AFR/EMR/SEAR)– Polio transition (AFR/EMR/SEAR)
20
Summary• Substantial progress in measles control/elimination since 2000
– Global number of cases and estimated deaths significantly reduced– Lowest ever measles incidence in WPR in 2017
• Concerns– Compared to 2016, resurgence of measles in 4 of the 6 Regions– Regional measles elimination can be achieved but sustainability
remains a challange– 2015 global milestones and 3 regional targets were not met
• The recent trends highlight the fragility of gains made in measles elimination– Urgent need to step up efforts towards achieving and sustaining the global and regional
goals.– Without strong and equitable routine systems, elimination, when achieved, is not likely to
be sustained.
21
Strengthening of RI Systems • RI is critical for achieving the elimination goals:
– > 95% coverage with 2 doses of MCV is needed – Central theme for M&R Initiative Strategic Plan (2012-2020) and ongoing activities– 2/3 of measles cases averted through RI (J. Inf Dis. 204, 2011)
• Studies demonstrate that properly planned SIAs can strengthening RI (E.g.,):– Improve micro-planning, training and supervision of HCW – Improvement of CC, waste management system & injection-safety standards– strengthened AEFI surveillance
• MCV2 in the 2YL offers an ideal opportunity by:– fixing an immunization/health check contact during 2YL (e.g. growth monitoring, booster
doses, Vit A)– catch-up vaccination for all missed vaccines
• Measles vaccination school entry checks can improve coverage of other VPDs.
• Measles Outbreaks as an indicators of weak RI:– Measles is highly infectious and seeks out susceptibles; disease is highly visible,– Outbreaks identifies gaps in RI programs and population groups missed by RI.
Challenge: Polio Transition
• 88% of estimated measles
deaths occur in these countries
• Most of the world’s rubella and
CRS cases (100,000)
• Polio field staff spend nearly
1/3 of their time working on RI
& MR.
• Critical for SIA quality and
surveillance
• Estimated $77 million (70%) of
annual needs for VPD/MR
surveillance are coming from
polio $$
• Over 2500 polio-funded staff
are supporting VPD/MR
surveillance
16 countries with largest polio assets
RISKS:• Polio virus transmission if re-introduced• Resurgence of measles and rubella
2017CAN=45USA=120ARG=3VEN=727Total=895
Distributionofconfirmedmeaslescasesbycountries.TheAmericas2017and2018*.
2017
2018*
2018Argentina= 11Antigua and Barbuda=1Brazil= 2,044Canada=25
Colombia=105; Ecuador=19; Guatemala=1Mexico= 5Peru= 36 USA=137Venezuela=4,605 (58 deaths) Total= 6,989
Sources: Surveillance country reports sent to the Immunization Unit of PAHO/WHO and Epidemiological Update of Measles*Data as of epidemiological week 40–2018. Report as 6 October 2018. Venezuela last updated until EW-32 2018.
active measles casesnon-active measles cases
l 1 confirmed case
Reported Measles Cases by Classification and Epidemiological Week.Venezuela EW-26, 2017 – EW-40, 2018
Source: Immunization Direction, Ministry of Popular Power for Health
n= 7068
Confirmed (5, 598)
• Clínic (3, 218)
• Laboratory (1,946)
• Epi Link (534)
2017 2018
n= 1451
Confirmed (727)
• Laboratory (507)
• Epi Link (220)
3 3 4 4 5 5 5 5 6 7 8 8 9 101012121315
17212222232424
26262626
35384042
44474752
0
20
40
60
80
100
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
RC
V1 c
over
age
(%)
Global AFR AMR EMR EUR SEAR WPR
Rubella containing vaccine 1st Dose (RCV1) coverage* by WHO region, 1980-2017global coverage at 52% in 2017
Source: WHO/UNICEF coverage estimates 2017 revision, July 2018.Immunization Vaccines and Biologicals, (IVB), World Health Organization.194 WHO Member States. Date of slide: 15 July 2018.
*coverage estimates for the 1st dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine.
0 2,100 4,2001,050 Kilometers
Immunization coverage with 2nd dose of measles containing vaccines by administered schedule, 2017
<50% (12 countries or 6%)50-79% (36 countries or 19%)80-89% (34 countries or 18%)90-94% (32 countries or 17%)
Not available/ Not introduced (27 countries or 14%)Not applicable
>=95% (50 countries or 26%)2nd dose of measles containing vaccines in schedule but no coverage data available (3 countries or 2%)
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2018. All rights reserved
Source: WHO/UNICEF coverage estimates 2017 revision, July 2018. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization. 194 WHO Member States. Date of slide: 15 July 2018
top related